Since the VHL E3 ligase is poorly expressed in platelets, BCL-XL PROTACs targeted for degradation by that ligase did not induce thrombocytopenia, maintaining the same therapeutic efficacy as VHL that is expressed in the lymphomatous cells [18]. Here, VHL is linked to Thrombocytopenia.